Free Trial
NYSEAMERICAN:MAIA

MAIA Biotechnology Q4 2023 Earnings Report

MAIA Biotechnology logo
$2.06 +0.15 (+7.85%)
Closing price 05/6/2025 04:10 PM Eastern
Extended Trading
$2.08 +0.02 (+1.21%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MAIA Biotechnology EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 20, 2024
Conference Call Time
7:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025

Conference Call Resources

MAIA Biotechnology Earnings Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA), a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

View MAIA Biotechnology Profile

More Earnings Resources from MarketBeat